NCT05371730View on ClinicalTrials.gov

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

May 30, 2025

Study Completion Date

April 30, 2026

Conditions
Relapsed / Refractory Myelodysplastic Syndromes
Interventions
DRUG

NCR300

Intravenous infusion of NK cells（NCR300）

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of University of Science and Technology of China

OTHER

lead

Nuwacell Biotechnologies Co., Ltd.

INDUSTRY